{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-021038","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-06-18T11:21:33+00:00","discovered_at":"2026-06-18T11:25:00.229030+00:00","generated_at":"2026-06-18T11:25:10.929269+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CervoMed receives US patent allowance for neflamapimod in dementia with Lewy bodies","bullets":["USPTO notice of allowance for patent covering neflamapimod for dementia with Lewy bodies in patients without substantial Alzheimer's tau pathology.","Expected to provide intellectual property protection into 2042, excluding potential patent term extension.","Patent protects use of drug candidate neflamapimod for this specific patient population."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-021038","json":"https://secwatch.observer/filing/0001437749-26-021038.json","markdown":"https://secwatch.observer/filing/0001437749-26-021038.md","text":"https://secwatch.observer/filing/0001437749-26-021038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926021038/0001437749-26-021038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926021038/crvo20260618c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:25:10.929269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}